KRN 2391

Drug Profile

KRN 2391

Alternative Names: KRN 2039

Latest Information Update: 22 Sep 2004

Price : $50

At a glance

  • Originator Kirin Brewery
  • Developer Kirin Brewery; Nippon Shinyaku
  • Class Anti-ischaemics; Antiarrhythmics; Antihypertensives; Ischaemic heart disorder therapies; Small molecules; Vasodilators
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Angina pectoris; Arrhythmias

Most Recent Events

  • 22 Sep 2004 Discontinued - Preclinical for Arrhythmias in Japan (unspecified route)
  • 22 Sep 2004 Discontinued - Phase-II for Angina pectoris in Japan (PO)
  • 14 Oct 1998 No Development Reported - Preclinical for Arrhythmias in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top